Aclarion Showcases Nociscan Technology and Essential Value Drivers at LSI Europe '25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Source: Globenewswire
Company Overview: Aclarion, Inc. is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and augmented intelligence through its platform, Nociscan, to help physicians identify painful discs in the lumbar spine.
Clinical Trial and Technology: The company is conducting a pivotal 300-patient CLARITY trial to assess the effectiveness of Nociscan in improving surgical outcomes for chronic low back pain, with interim results expected in Q2 2026.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
